Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort Study.

Abstract

BACKGROUND:

Testicular germ cell cancer (TC) incidence peaks during reproductive age, but knowledge on fertility after treatment is insufficient. The aim was to evaluate paternity after today's TC treatment.

METHODS:

Clinical data were extracted from the Danish Testicular Cancer database, and patients were divided into 4 groups: 1) surveillance; 2) bleomycin, etoposide, and cisplatin (BEP); 3) BEP + postchemotherapy retroperitoneal surgery (BEP + surgery); and 4) abdominal radiotherapy. For each patient, 10 men matched on date of birth were randomly sampled from the normal population. Paternity was defined as date of birth of first child after TC treatment with or without the use of assisted reproductive technology and was assessed by linkage to the Danish Medical Birth Register and the Danish in vitro fertilization register.

RESULTS:

We included 4846 unilateral TC patients and 48 456 men from the normal population. The 20-year predicted chance of obtaining fatherhood for a 30-year-old man was 39.7% in TC patients compared with 42.5% in the normal population. The chance of obtaining fatherhood was statistically significantly decreased after BEP (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.78 to 0.97) and BEP + surgery (HR = 0.74, 95% CI = 0.63 to 0.87), but not after radiotherapy (HR = 0.89, 95% CI = 0.75 to 1.06) or surveillance (HR = 0.95, 95% CI = 0.89 to 1.02). The risk of needing assisted reproductive technology to obtain fatherhood was increased after all treatment modalities.

CONCLUSIONS:

The chance of obtaining fatherhood after TC treatment was substantially higher than previously reported. Patients followed on a surveillance program had a similar chance of obtaining fatherhood as noncancerous men.

• Authors: Mikkel Bandak, Allan Jensen, Christian Dehlendorff, Jakob Lauritsen, Michael Kreiberg, Thomas Wagner, Josephine Rosenvilde, Gedske Daugaard
• Journal: Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 114 Issue 1 Pg. 149-155 (01 11 2022) ISSN: 1460-2105 [Electronic] United States
• PMID: 34180995 (Publication Type: Case Reports, Journal Article)
• Copyright: © The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

Chemical References

• Bleomycin
• Etoposide
• Cisplatin

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bleomycin
• Child
• Cisplatin
• Cohort Studies
• Denmark (epidemiology)
• Etoposide
• Humans
• Male
• Neoplasms, Germ Cell and Embryonal (epidemiology, surgery)
• Paternity
• Testicular Neoplasms (epidemiology, radiotherapy, surgery)